We are live on ! Find out more
FPRX

Five Prime Therapeutics, Inc.
FPRX

Delisted

FPRX was delisted on the 15th of April, 2021.

Back to rankings

0 hedge funds and large institutions have $0 invested in Five Prime Therapeutics, Inc. in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 147 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 147 → 0 (-147)

100% less funds holding in top 10

Funds holding in top 10: 5 → 0 (-5)

100% less capital invested

Capital invested by funds: $1.56B → $0 (-$1.56B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 147

Holders
–
Holders Change
-147
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
147
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$239M
2
BlackRock
BlackRock
New York
-$116M
3
RSCM
Rock Springs Capital Management
Maryland
-$100M
4
MF
Magnetar Financial
Illinois
-$90.6M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$81.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
76
Natixis
France
– -$1.73M -45,887 Closed
SG Americas Securities
77
SG Americas Securities
New York
– -$1.53M -40,648 Closed
Jane Street
78
Jane Street
New York
– -$1.35M -35,842 Closed
SEI Investments
79
SEI Investments
Pennsylvania
– -$576K -33,856 Closed
Susquehanna International Group
80
Susquehanna International Group
Pennsylvania
– -$1.13M -29,986 Closed
New York State Common Retirement Fund
81
New York State Common Retirement Fund
New York
– -$1.11M -29,500 Closed
T. Rowe Price Associates
82
T. Rowe Price Associates
Maryland
– -$1.05M -27,983 Closed
BCM
83
BCK Capital Management
Connecticut
– -$979K -26,000 Closed
Millennium Management
84
Millennium Management
New York
– -$965K -25,616 Closed
AC
85
Athanor Capital
New York
– -$872K -23,159 Closed
Deutsche Bank
86
Deutsche Bank
Germany
– -$844K -22,408 Closed
B
87
Bailard
California
– -$829K -22,000 Closed
Voloridge Investment Management
88
Voloridge Investment Management
Florida
– -$806K -21,387 Closed
Allianz Asset Management
89
Allianz Asset Management
Germany
– -$791K -21,000 Closed
BNP Paribas Financial Markets
90
BNP Paribas Financial Markets
France
– -$772K -20,503 Closed
CSS
91
Cubist Systematic Strategies
Connecticut
– -$766K -20,329 Closed
SMC
92
S. Muoio & Co
New York
– -$753K -20,000 Closed
AIG
93
American International Group
New York
– -$705 -18,705 Closed
Nomura Holdings
94
Nomura Holdings
Japan
– -$668K -18,250 Closed
JG
95
Jefferies Group
New York
– -$683K -18,132 Closed
Manulife (Manufacturers Life Insurance)
96
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$683K -18,120 Closed
VEA
97
Virtus ETF Advisers
New York
– -$645K -17,112 Closed
GH
98
GAM Holding
Switzerland
– -$633K -16,800 Closed
Los Angeles Capital Management
99
Los Angeles Capital Management
California
– -$595K -15,793 Closed
CC
100
Centiva Capital
New York
– -$565K -15,000 Closed
2 3
4
5 6

FPRX Hedge Fund Activity: Q2 2021 in Review

0 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q2 2021, worth a combined $0 — down 100% from $1.56B a quarter earlier.

Sellers outnumbered buyers: 147 funds closed out of FPRX and 0 opened new positions — a net loss of 147 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BVF Inc, exiting entirely with an estimated $239M sold.

  • 0 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q2 2021, down from 147 in Q1 2021.
  • Funds reported $0 of Five Prime Therapeutics, Inc. stock for Q2 2021, down 100% quarter-over-quarter.
  • 0 funds opened new Five Prime Therapeutics, Inc. positions in Q2 2021 and 147 closed out, a net change of -147 holders.
  • The largest Five Prime Therapeutics, Inc. seller in Q2 2021 was BVF Inc, an estimated $239M sold.

Based on aggregated 13F filings for Q2 2021.